Biolife Solutions (BLFS) Environmental, Social & Governance (ESG) Data

On June 9, 2022, BioLife Solutions, Inc. (the “Company”) completed its 2022 annual meeting of stockholders (the “Annual Meeting”). The number of shares of stock entitled to vote at the Annual Meeting was 42,858,120 consisting of 42,394,243 shares of common stock, par value $0.01 per share (the “Common Stock”) of the Company and 463,877 shares of unvested restricted stock (collectively, the “Voting Stock”) of the Company. The number of shares of Voting Stock present or represented by valid proxy at the Annual Meeting was 31,119,859 shares. At the Annual Meeting, the Company’s stockholders (i) re-elected each of Michael Rice, Joydeep Goswami, Joseph Schick, Amy DuRoss and Rachel Ellingson as directors, (ii) approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, (iii) ratified the appointment by the board of directors (the “Board”) of the Company of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022, and (iv) approved an amendment to the Company’s Second Amended and Restated 2013 Performance Incentive Plan to increase the aggregate number of shares of Common Stock which may be issued under the plan by 2,000,000 shares of Common Stock from 6,500,000 to 8,500,000 shares of Common Stock. The following is a tabulation of the voting on the proposals presented at the Annual Meeting:

Proposal No. 1 – Election of directors

Michael Rice, Joydeep Goswami, Joseph Schick, Amy DuRoss, and Rachel Ellingson were elected to serve until the 2023 annual meeting of stockholders or until his or her successor is duly elected and qualified or until his or her earlier resignation or removal or otherwise is disqualified from serving as a director of the Company. The voting results were as follows:



Proposal No. 2 – Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers

The compensation for the Company’s named executive officers, by non-binding advisory vote, was approved. The voting results were as follows:



Proposal No. 3 – Ratification of the appointment by the Board of the Company of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022

The ratification of the appointment by the Company’s Board of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022, was approved. The voting results were as follows:



Proposal No. 4 – Approval of an amendment to the Second Amended and Restated 2013 Performance Incentive Plan to increase the aggregate number of shares of Common Stock which may be issued under the plan by 2,000,000 shares of Common Stock from 6,500,000 shares of Common Stock to 8,500,000 shares of Common Stock

The Amendment to the Second Amended and Restated 2013 Performance Incentive Plan to increase the aggregate number of shares of Common Stock which may be issued under the plan by 2,000,000 shares of Common Stock from 6,500,000 shares of Common Stock to 8,500,000 shares of Common Stock was approved. The voting results were as follows: